targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
Published 1 year ago • 106 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
2:05
phase iii trial of azacitidine and gilteritinib in flt3 mutant aml
-
2:42
triplet combination of azacitidine, venetoclax & gilteritinib for patients with flt3-mutated aml
-
2:38
nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast ca...
-
2:50
gilteritinib plus azacitidine versus azacitidine monotherapy for newly diagnosed flt3-mutated aml
-
3:28
bax-mediated bh3 mimetic resistance in aml
-
4:44
azacitidine quizartinib for patients with mds and mpns with flt3 or cbl mutation
-
1:23
the promise of combining venetoclax with gilteritinib for the treatment of flt3-mutated aml
-
5:49
neoadjuvant treatment for triple-negative breast cancer
-
10:15
quizartinib for flt3-mutated aml
-
32:44
flotetuzumab (flz), an investigational cd123 x cd3 bispecific dart® protein-induced clustering...
-
4:18
second-generation flt3 inhibitors in aml: quizartinib
-
8:54
lydia petricca: using fus to immunologically control triple negative breast cancer
-
1:24
combining chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
5:07
relapsed vs. refractory data for flt3 inhibitors in aml
-
2:48
immunomodulatory effects of parp inhibition in brca1-deficient triple-negative breast cancer
-
4:15
phase ib/ii trial of quizartinib, decitabine and venetoclax in flt3-itd-mutated aml
-
4:17
adaptive tonic trial of nivolumab combinations for breast cancer
-
3:14
resistance mechanisms to flt3 inhibitors in aml
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml